Antitrust Antitrust

Leadiant to challenge Dutch fine over excessive prices for orphan drug CDCA

By Tono Gil and Lewis Crofts
  • 19 Jul 2021 08:48
  • 19 Jul 2021 09:15
Leadiant has said it will challenge a fine of about 19 million euros ($22 million), which the Dutch antitrust watchdog imposed today over excessive prices for its orphan drug CDCA.

The Authority for Consumers and Markets said that Leadiant held a dominant position on CDCA-based drugs for the treatment of the rare hereditary metabolic disorder

To view the latest version of this document and thousands of others like it, sign-in to MLex or register for a free trial.

Discover MLex

Stay on top of global regulatory developments

LEARN MORE LEARN MORE

Latest News